Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab

PURPOSE: To assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (). EXPERIMENTAL DESIGN: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Joseph, Richard W., Elassaiss-Schaap, Jeroen, Kefford, Richard, Hwu, Wen-Jen, Wolchok, Jedd D., Joshua, Anthony M., Ribas, Antoni, Hodi, F. Stephen, Hamid, Omid, Robert, Caroline, Daud, Adil, Dronca, Roxana, Hersey, Peter, Weber, Jeffrey S., Patnaik, Amita, de Alwis, Dinesh P., Perrone, Andrea, Zhang, Jin, Kang, S. Peter, Ebbinghaus, Scot, Anderson, Keaven M., Gangadhar, Tara C.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916264/
https://ncbi.nlm.nih.gov/pubmed/29685882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2386
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares